Phase IIISmall Molecule
Compound 61658
Formula Pending
Molecular Mass
N/A
CAS Registry
AUTO-061658
Risk Class
MODERATE
Last Audit
May 29, 2108
Research Abstract
Small Molecule candidate engineered for oncology adjuvant initiatives with automated dossier coverage.
Compound 61658 is a small molecule asset inside small molecule innovation track initiatives, optimized for oncology adjuvant and inflammation control.
The dossier currently sits in phase iii with a moderate risk rating, meaning it is requires layered oversight with metabolic labs.
Supply records cite CAS AUTO-061658 with updates logged 2108-05-29.
Acquisition Protocol
Authorized research personnel may request deployment of this compound for laboratory analysis.
Primary Vectors
Oncology adjuvantInflammation control
Nomenclature
CX-61658Small Molecule Program 61658
Reference Material
- [1] Anubis Compound Registry • CAS AUTO-061658
- [2] Operations Pulse • Small Molecule innovation track
- [3] Risk Governance Ledger • MODERATE clearance for COMPOUND-61658